Impetigo
📧 Sign up to get email alerts when something new happens for Impetigo.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
A completed clinical trial evaluating Legit.Health Plus Support as a diagnostic aid for generalized pustular psoriasis and other skin condit…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Perspectives on Antibiotics and Tracking Symptoms in Children [NA]
A pediatric clinical trial update from Murdoch Children's Research Institute describes an ongoing study on antibiotics and symptom tracking …
-
FDA approval · 2025-05-13FDA Approved: MUPIROCIN — Original Application (Encube Ethicals, Inc.)
FDA approves Encube Ethicals, Inc.'s original application for mupirocin topical antibiotic (generic mupirocin).
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care [NA]
A completed clinical trial assessed reducing antibiotic duration for skin and soft tissue infections in primary care using behavioral econom…
-
FDA approval · 2024-07-08FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Mupirocin by Glenmark Pharmaceuticals Inc., USA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-03FDA Approved: MUPIROCIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for mupirocin from Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2022-11-15FDA Approved: MUPIROCIN — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for mupirocin from Amneal Pharmaceuticals NY LLC (generic mupirocin).
-
FDA approval · 2021-11-16FDA Approved: MUPIROCIN — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' original ANDA for mupirocin topical ointment, authorizing its marketing as a generic antibiotic fo…
-
FDA approval · 2021-08-04FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark Pharmaceuticals Inc., USA's supplemental application for mupirocin.
-
CLINICAL_TRIALS trial_result · 2021-03-12Clinical Trial Update: Safety and Efficacy of Mupirocin Gel in Children With Impetigo [Phase 3]
Phase 3 trial update assessing safety and efficacy of mupirocin gel in children with impetigo has completed.
-
FDA approval · 2020-04-27FDA Approved: MUPIROCIN — Original Application (NORTHSTAR RX LLC)
FDA approved the original application for mupirocin calcium (Mupirocin) by NorthStar RX LLC, enabling a generic topical antibiotic for skin …
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: Azithromycin - Ivermectin Mass Drug Administration for Skin Disease [Phase 4]
Phase 4 trial update evaluating azithromycin-ivermectin mass drug administration for skin diseases, including scabies and yaws, with results…
-
FDA approval · 2019-07-16FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Mupirocin from Glenmark Pharmaceuticals Inc., USA. This approval updates the existing ANDA produ…
-
EMA withdrawal · 2019-03-15EMA Withdrawn: Altargo (retapamulin) — Glaxo Group Ltd
The EMA withdrew Altargo (retapamulin) from the market for impetigo and staphylococcal skin infections.
-
FDA approval · 2018-10-30FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark Pharmaceuticals Inc., USA's supplemental application for mupirocin (generic topical ointment) under ANDA 201587. This …
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo [Phase 2]
Phase 2 study assessing safety, tolerability, PK, and activity of topical ATx201 Gel in outpatients with impetigo has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) [Phase 2]
Phase 2 trial results for TD1414 2% cream in impetigo and secondarily infected traumatic lesions report efficacy, safety, and tolerability.
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo [Phase 2]
Phase 2 pharmacokinetics study of 2% TD1414 cream in adults with secondarily infected traumatic lesions and impetigo has completed with resu…
-
CLINICAL_TRIALS trial_result · 2017-01-23Clinical Trial Update: Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo [Phase 3]
A Phase 3 trial update for SB-275833 ointment 1% for impetigo (a bacterial skin infection) is reported as completed, under GlaxoSmithKline.
-
FDA approval · 2016-12-06FDA Approved: MUPIROCIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for mupirocin by Padagis Israel Pharmaceuticals Ltd.
-
CLINICAL_TRIALS trial_result · 2016-09-23Clinical Trial Update: Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment [Phase 3]
Phase 3 trial evaluating SB-275833 1% topical ointment versus placebo for impetigo has completed.
-
CLINICAL_TRIALS trial_result · 2016-05-19Clinical Trial Update: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo [Phase 3]
Phase 3 trial comparing ozenoxacin 1% cream with placebo in impetigo shows efficacy and safety results.
-
CLINICAL_TRIALS trial_result · 2016-05-18Clinical Trial Update: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo [Phase 3]
Phase 3 trial comparing ozenoxacin 1% cream to placebo in impetigo assessed efficacy and safety, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection [Phase 4]
Phase 4 trial update on twice-daily application of Altabax for uncomplicated soft tissue infections, including impetigo and folliculitis, wi…
-
FDA approval · 2016-01-05FDA Approved: MUPIROCIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's supplemental application for a generic mupirocin product (ANDA 090480).